Diabetic kidney disease

Byaibio

Diabetic kidney disease (DKD) is a common microvascular complication of diabetes and a leading cause of end-stage renal disease, as well as a major contributor to chronic kidney disease globally. A key pathogenic mechanism highlighted here is cellular senescence, which is described as a recognized driver of DKD pathogenesis and a therapeutic target for senotherapeutic and regenerative approaches. The literature also emphasizes mitochondrial and metabolic mechanisms, including the sodium glucose linked transporter 2 inhibitor class of renoprotective therapies and the NAD+-SIRT3 axis as a way to mitigate metabolic memory in progressive diabetic renal disease. In addition, tissue-engineering strategies using hydrogels and scaffolds, and cell-based therapies such as mesenchymal stem stromal cells and extracellular vesicles, are being explored for renal repair. A specific herbal intervention, suoquan yishen formula, has been reported to attenuate ectopic lipid deposition by inhibiting UBC9-mediated SUMO1 modification of DRP1, linking lipid handling to mitochondrial dynamics in DKD. Overall, recent reviews frame DKD as a disease of chronic metabolic injury, senescence, and mitochondrial dysfunction, with emerging therapies aiming to restore renal homeostasis rather than only lower glucose.

Cellular senescence and regenerative therapy

  • A 2026 Kidney International review (PMID:41581730) identifies cellular senescence as a recognized driver of DKD pathogenesis and discusses regenerative, cell-based, and senotherapeutic strategies.
  • The same review (PMID:41581730) positions DKD as a primary global cause of chronic kidney disease and a major target for anti-senescence intervention.
  • Senescence-focused approaches are presented as potentially disease-modifying rather than purely symptomatic in DKD (PMID:41581730).

Mitochondrial and metabolic mechanisms

  • A 2026 Renal Failure review (PMID:41633353) focuses on mitochondrial quality control in DKD, highlighting mitochondrial dysfunction as a therapeutic opportunity.
  • Another 2026 Renal Failure paper (PMID:41991506) proposes targeting the NAD+-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease.
  • The metabolic-memory concept is specifically linked to progressive renal disease in diabetes, suggesting persistent epigenetic/metabolic injury beyond glycemic control (PMID:41991506).
  • suoquan yishen formula attenuated ectopic lipid deposition by inhibiting UBC9-mediated SUMO1 modification of DRP1 in DKD (PMID:41461331).

Renoprotective and tissue-engineering approaches

  • sodium glucose linked transporter 2 inhibitor therapies are discussed as renoprotective treatments in DKD, including mitochondria-targeted SGLT2 inhibitors with positive effects in animal experiments or clinical trials.
  • mesenchymal stem stromal cells are described as commonly studied cellular therapies for DKD, reflecting interest in paracrine and regenerative mechanisms.
  • extracellular vesicles derived from mesenchymal stem/stromal cells are also commonly studied in DKD, likely as cell-free regenerative therapeutics.
  • hydrogels and scaffolds are biomaterials used in tissue-engineering approaches for DKD, supporting delivery and renal repair strategies.